Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

(2009) Anne Catherine Sprynski et al.   BLOOD

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

(2009) D. W. McMillin et al.   CANCER RESEARCH

Multiple Myeloma

(2009) S. Vincent Rajkumar   CURRENT PROBLEMS IN CANCER

Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line

(2009) Shuqing Lü et al.   EXPERIMENTAL HEMATOLOGY

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

Characterization of the ubiquitin–proteasome system in bortezomib-adapted cells

(2009) T Rückrich et al.   LEUKEMIA

Proteasome inhibitors in the treatment of multiple myeloma

(2009) J J Shah et al.   LEUKEMIA

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia

(2009) Jacob P. Laubach et al.   LEUKEMIA & LYMPHOMA

A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data

(2009) Nuno L. Barbosa-Morais et al.   NUCLEIC ACIDS RESEARCH

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

(2008) Deborah J. Kuhn et al.   BLOOD

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Statistical issues in the analysis of Illumina data

(2008) Mark J Dunning et al.   BMC BIOINFORMATICS

Proteasome   Subunit Pharmacogenomics: Gene Resequencing and Functional Genomics

(2008) L. Wang et al.   CLINICAL CANCER RESEARCH

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

(2008) R. Z. Orlowski et al.   CLINICAL CANCER RESEARCH

Insulin-Like Growth Factor-I Activates Gene Transcription Programs Strongly Associated With Poor Breast Cancer Prognosis

(2008) Chad J. Creighton et al.   JOURNAL OF CLINICAL ONCOLOGY

Insulin-like growth factor-1 delays Fas-mediated apoptosis in human neutrophils through the phosphatidylinositol-3 kinase pathway

(2008) Eddy Himpe et al.   JOURNAL OF ENDOCRINOLOGY

Point Mutation of the Proteasome  5 Subunit Gene Is an Important Mechanism of Bortezomib Resistance in Bortezomib-Selected Variants of Jurkat T Cell Lymphoblastic Lymphoma/Leukemia Line

(2008) S. Lu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

In vitro activity of bortezomib in cultures of patient tumour cells—potential utility in haematological malignancies

(2008) Kristina Wiberg et al.   MEDICAL ONCOLOGY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Enhanced identification and biological validation of differential gene expression via Illumina whole-genome expression arrays through the use of the model-based background correction methodology

(2008) Liang-Hao Ding et al.   NUCLEIC ACIDS RESEARCH

Canonical and non-canonical JAK–STAT signaling

(2008) Willis X. Li   TRENDS IN CELL BIOLOGY